Supervivencia de pacientes con cáncer de mama y cirugía conservadora / Survival in Patients with Breast Cancer and Conservative Surgery

Introducción: En la actualidad la cirugía conservadora, más que una opción en el tratamiento quirúrgico del cáncer de mama, es la técnica quirúrgica de elección. Objetivo: Caracterizar la supervivencia de los pacientes con cáncer de mama operados con cirugía conservadora. Métodos: Se realizó un estudio multicéntrico, retrospectivo descriptivo de corte longitudinal, en el Hospital Universitario Clínico Quirúrgico "Arnaldo Milián Castro" y el oncológico "Celestino Hernández Robau", ambos de la ciudad de Santa Clara provincia Villa Clara, en el período comprendido desde enero del 2011 hasta diciembre del 2020. Resultados: La supervivencia global de los pacientes con cáncer de mama y cirugía conservadora en aquellos que presentaron eventos (fallecidos) fue mayor en los portadores de carcinoma ductal infiltrante con 9,3 años. En el caso del estadio tumoral predominó la supervivencia en aquellos pacientes que estaban en estadios Ia y IIa con 9,8 y 9,1 años, respectivamente. Según la inmunohistoquímica, el subtipo molecular con mejor supervivencia global fue el Luminal B con 9,2 años. En cuanto al tratamiento definitivo aplicado presentaron mayor supervivencia global aquellos pacientes que recibieron esquemas de quimioterapia+ radioterapia+ hormono terapia y quimioterapia+ radioterapia con 9,4 y 8,8 años, respectivamente. Conclusiones: Existe una mayor supervivencia global en aquellos pacientes con carcinoma ductal infiltrantes (NOS), estadios tumorales Ia y IIa, con subtipo molecular Luminal B según inmunohistoquímica y con tratamientos definitivos de quimioterapia+ radioterapia+ hormonoterapia(AU)

Introduction: Nowadays, conservative surgery, rather than an option for the surgical treatment of breast cancer, is the surgical technique of choice. Objective: To characterize the survival of patients with breast cancer operated on with conservative surgery. Methods: A multicenter, retrospective, descriptive and longitudinal study was carried out at Hospital Universitario Clínico Quirúrgico "Arnaldo Milián Castro" and "Celestino Hernández Robau" oncologic hospital, both in the city of Santa Clara, Villa Clara Province, in the period from January 2011 to December 2020. Results: The overall survival of patients with breast cancer and conservative surgery in those who presented events (died) was higher in those with infiltrating ductal carcinoma, accounting for 9.3 years. In the case of tumor stage, survival was predominant in those patients with stages IA and IIA, accounting for 9.8 and 9.1 years, respectively. Concerning immunohistochemistry, the molecular subtype with the best overall survival was Luminal B, accounting for 9.2 years. Regarding the applied definitive treatment, those patients who received chemotherapy-radiotherapy-hormone therapy and chemotherapy-radiotherapy schemes presented better overall survival, accounting for 9.4 and 8.8 years, respectively. Conclusions: Overall survival is higher in patients with infiltrating ductal carcinoma (not otherwise specified), tumor stages IA and IIA, molecular subtype Luminal B according to immunohistochemistry, and definitive treatments with chemotherapy, radiotherapy, hormone therapy scheme(AU)

Factors influencing decisions on contralateral symmetrisation procedure among patients with breast cancer

INTRODUCTION@#Oncoplastic breast-conserving surgery (OBCS) can cause breast asymmetry. Although contralateral breast surgery to achieve symmetry was offered to these patients, the uptake of symmetrisation was variable. We aimed to determine the factors that deter patients with breast cancer undergoing OBCS from opting for symmetrisation.@*METHODS@#All patients with breast cancer who underwent OBCS of displacement type with no symmetrisation were prospectively surveyed to explore the social, economic, psychological and physical reasons against symmetrisation.@*RESULTS@#A total of 28 patients participated in a survey administered at a mean 21.6 (range 2-47) months after OBCS. A combination of factors, such as worry and desire to treat breast cancer first (67.9%), not being overly concerned about breast cosmesis (57.1%) and fear of pain from additional operation (28.6%), deterred patients from immediate symmetrisation. Worry and desire to treat breast cancer first was the most important single factor for 50% of the patients. Reasons for no delayed symmetrisation included not being overly concerned about breast cosmesis (70.4%), fear of breast cancer recurrence (48.1%) and being happy with current breast cosmesis (33.3%), with the former two reasons equally cited as the single most important deterrent by 30% of patients each.@*CONCLUSION@#A combination of factors may deter patients from symmetrisation. The most significant factors deterring OBCS among patients were worry and desire to treat breast cancer first for immediate symmetrisation, and not being overly concerned about breast cosmesis and fear of breast cancer recurrence for delayed symmetrisation. Reassuring these patients may increase their uptake of symmetrisation, thereby improving patient cosmesis and satisfaction.

Resultado oncológico de cirugía conservadora con adyuvancia en cáncer de mama, Hospital San Felipe, Tegucigalpa / Oncologic outcome of conservative surgery with adjuvancy in breast cancer, Hospital San Felipe, Tegucigalpa

Antecedentes: El cáncer de mama es la malignidad más frecuentemente diagnosticada en mujeres, representando casi 1 de cada 4 casos de cáncer. Objetivo: Describir los resul-tados oncológicos de las pacientes tratadas con cirugía conser-vadora y adyuvancia por cáncer de mama estadios clínicos I-II, Hospital San Felipe, Tegucigalpa, 2017-2019. Métodos: Estudio descriptivo transversal retrospectivo. Extracción de información de expedientes clínicos de pacientes con diagnostico nuevo de cáncer de mama. Se registró datos sociodemográficos, estadio clínico pre- y post-operatorio, tratamiento y sobrevida. Resul-tados: De 49 pacientes, 59.2% (29) >50 años, 71.4% (35) pro-cedencia urbana, 61.2% (30) estadio IIA, las modalidades tera-péuticas fueron radioterapia 73.5% (36), hormonoterapia 69.4% (34), quimioterapia 40.8% (20). La combinación más frecuente fue radioterapia/hormonoterapia 46.9% (23); 26.5% (13) recibió monoterapia. El tiempo promedio de inicio de radioterapia fue 25 semanas (rango 4-90 semanas) y 13 semanas (rango 4-35 sema-nas) para quimioterapia. La sobrevida a 36 meses en estadio IA y IIB con adyuvancia fue 100.0% (5) y 86.0% (12), respectivamen-te. La sobrevida global a 36 meses fue 95.9% (47). Discusión: La sobrevida global identificada es comparable a estudios que si-guen las guías internacionales. Recomendamos implementar las recomendaciones de las guías internacionales para el manejo de cáncer de mama estadios tempranos, donde la adyuvancia debe iniciar en un periodo no mayor a 8 semanas postoperatorias. Este manejo contribuiría a reducir la morbilidad y el impacto psicoso-cial que presentan abordajes terapéuticos más radicales. Es ne-cesario y urgente contar con equipo y medicamentos adyuvantes de acuerdo a los avances científicos y tecnológicos...(AU)

Whole sequencing of the mitochondrial genome of breast cancer tissue in Mexican-mestizo postmenopausal women with different body mass index

Abstract Background Mitochondrial and oxidative stress has been related to obesity and breast cancer being this cancer more frequent and more aggressive in postmenopausal women with obesity. Objective The objective of this study was to investigate whether Mexican-Mestizo postmenopausal women with breast cancer and obesity present different somatic mutations in the mitochondrial DNA (mtDNA) when compared to women with normal body mass index (BMI). Subjects and Methods We included six Mexican-Mestizo postmenopausal women bearing breast cancer and who underwent mastectomy or breast-conserving surgery. BMI was determined in each case. Patients’ genomic DNA was isolated from blood leukocytes and tumor tissue samples. Whole mtDNA sequence was determined by MitoChip v2.0 mitochondrial resequencing array, and data were analyzed using the GeneChip Sequence Analysis Software. Tumor mtDNA sequence was compared with matched leukocyte mtDNA sequence. Results Three women had a normal BMI and three presented obesity. Overall, we found 64 genetic variants: 53.1% were somatic mutations and 46.9% were polymorphisms; 44.1% were in the non-coding region and 55.9% were in genes that encode for mitochondrial proteins. Among the somatic mutations, 67.7% were in patients with normal BMI and 32.3% in patients with obesity. Conclusions We did not find a higher frequency of mitochondrial somatic mutations in postmenopausal women with breast cancer and obesity compared to those with normal BMI. However, results could be due to the small number of women studied.

Segmentectomia pulmonar anatômica robótica: aspectos técnicos e desfechos / Robotic anatomic pulmonary segmentectomy: technical approach and outcomes

RESUMO Objetivo: relatar nossa experiência inicial com a segmentectomia robótica, descrevendo a técnica operatória, a colocação preferencial dos portais, os resultados iniciais e desfechos. Métodos: dados clínicos de pacientes submetidos à segmentectomia robótica, entre janeiro de 2017 e dezembro de 2018, foram obtidos de um banco de dados prospectivo de cirurgia robótica. Todos os pacientes tinham câncer de pulmão, primário ou secundário, ou doenças benignas, e foram operados usando o sistema Da Vinci com a técnica de três portais mais uma incisão utilitária de 3cm. As estruturas hilares foram dissecadas individualmente e as ligaduras dos ramos arteriais e venosos, dos brônquios segmentares, assim como, a transecção do parênquima, realizadas com grampeadores endoscópicos. Dissecção sistemática dos linfonodos mediastinais foi realizada para os casos de câncer de pulmão não de pequenas células (CPNPC). Resultados: quarenta e nove pacientes, dos quais 33 mulheres, foram submetidos à segmentectomia robótica. A média de idade foi de 68 anos. A maioria dos pacientes tinha CPNPC (n=34), seguido de doença metastática (n=11) e doenças benignas (n=4). Não houve conversão para cirurgia aberta ou vídeo, ou conversão para lobectomia. A mediana do tempo operatório total foi de 160 minutos e do tempo de console foi de 117 minutos. Complicações pós-operatórias ocorreram em nove pacientes (18,3%), dos quais sete (14,2%) tiveram internação prolongada (>7 dias) devido à fístula aérea persistente (n=4; 8,1%) ou complicações abdominais (n=2; 4%). Conclusão: a segmentectomia robótica é um procedimento seguro e viável, oferecendo curto período de internação e baixa morbidade.

ABSTRACT Objective: to report our initial experience with pulmonary robotic segmentectomy, describing the surgical technique, the preferred positioning of portals, initial results and outcomes. Methods: we collected data, from a prospective robotic surgery database, on patients undergoing robotic segmentectomy between January 2017 and December 2018. All patients had lung cancer, primary or secondary, or benign diseases, and were operated on with the Da Vinci system, by the three portals technique plus one utilitarian incision of 3cm. We dissected the hilar structures individually and performed the ligatures of the arterial and venous branches, of the segmental bronchi, as well as a parenchymal transection, with endoscopic staplers. We carried out systematic dissection of mediastinal lymph nodes for non-small cell lung cancer (NSCLC) cases. Results: forty-nine patients, of whom 33 were women, underwent robotic segmentectomy. The average age was of 68 years. Most patients had NSCLC (n=34), followed by metastatic disease (n=11) and benign disease (n=4). There was no conversion to laparoscopic or open surgery, or to lobectomy. The median total operative time was 160 minutes, and the median console time, 117 minutes. Postoperative complications occurred in nine patients (18.3%), of whom seven (14.2%) had prolonged hospitalization (>7 days) due to persistent air fistula (n=4; 8.1%) or abdominal complications (n=2.4%). Conclusion: robotic segmentectomy is a safe and viable procedure, offering a short period of hospitalization and low morbidity.

Alternativa técnica para tratamento de esteatonecrose em mama: descrição e resultados / Alternative technique for the treatment of osteonecrosis in breasts: description and results

Introdução: Este trabalho descreve e apresenta os resultados de uma técnica alternativa para tratamento da esteatonecrose, a lipoaspiração com cânula específica, com bons resultados observados no exame físico e de imagem. A esteatonecrose é uma complicação que ocorre com alguma frequência nas cirurgias mamárias, principalmente nas reconstruções mamárias, nas cirurgias conservadoras ou TRAM, caracterizando-se, inicialmente, por endurecimento de uma região, que evolui para uma nodulação de tamanhos variados, em qualquer região mamária, com cistos oleosos e fibrose, que traduz uma preocupação constante por parte das pacientes, do oncologista, do mastologista e do cirurgião plástico devido à ocorrência de recidiva tumoral. Método: Foi realizada uma revisão retrospectiva dos prontuários das pacientes submetidas a procedimentos nas mamas, seja reconstrução ou estética, e evoluíram com esteatonecrose, sendo submetidas ao tratamento com lipoaspiração, inspirada na técnica de perfuração óssea para tratamento de necrose óssea, realizado por ortopedistas. Resultados: No período englobado, 8 pacientes foram selecionadas. A idade média foi de 56 anos. Grande parte possuía alguma deformidade na mama acometida, sendo o cisto oleoso o mais comum - 5 pacientes (62,5%). 75% possuíam história de neoplasia mamária. Conclusão: A individualização do paciente é a chave para o sucesso do tratamento da esteatonecrose e uma ferramenta essencial para atender às expectativas e anseios da paciente após essa complicação. Cada técnica tem suas indicações, vantagens e limitações, que devem ser amplamente discutidas com o paciente visando o melhor resultado possível.

Introduction: This work describes and presents the results of an alternative technique for treating steatonecrosis by liposuction using a specific cannula, with good physical and imaging results. Steatonecrosis is a complication that frequently occurs during mammary surgeries, especially during mammary reconstructions and in conservative surgery or TRAM. Steatonecrosis is characterized initially by hardening of the tissue that may develop into nodules of different sizes in any mammary region with oily cysts and fibrosis; consequently, steatonecrosis is a constant concern for patients, oncologists, breast cancer specialists, and plastic surgeons due to the possibility of tumor recurrence. Method: A retrospective review of the medical records of the patients undergoing procedures related to the breast, either reconstructive or aesthetic, was performed. Patients who developed steatonecrosis and were treated by liposuction, similar to the bone drilling technique performed by orthopedic surgeons for the treatment of bone necrosis, were included in the study. Results: Eight patients from the study period reviewed were selected. The mean age was 56 years. Most of the patients showed deformity in the affected breast, with oily cysts, reported in 5 patients (62.5%), being the most common deformity. Breast cancer history was reported for 75% of the patients. Conclusion: The individualization of the patient is the key to successful treatment of steatonecrosis and an essential tool to satisfy the expectations and desires of the patient after this complication. Each technique has its indications, advantages and limitations, which should be thoroughly discussed with the patient to obtain the best possible result.

Percepção dos internos de uma faculdade de medicina sobre o câncer de mama e reconstrução mamária / Perception of breast cancer and breast reconstruction in medical school students

Introdução: O câncer de mama é o tipo mais comum entre as mulheres no mundo e no Brasil, depois do câncer de pele não melanoma. O objetivo é avaliar a percepção dos estudantes de medicina sobre o câncer de mama e reconstrução mamária. Métodos: Trata-se de estudo transversal piloto composto por alunos do 5º e 6º ano de curso de medicina, realizado de maio de 2016. Resultados: Foi questionado se há possibilidade de reconstrução mamária após a mastectomia, sendo que de forma unânime 100% foi sim. Para melhor caracterização, foi perguntado se a reconstrução pode ser feita no mesmo momento da mastectomia, 69 (57,5%) estudantes marcaram sim e 51 (42,5%) negaram. Em análise aos conhecimentos cirúrgicos, foi perguntado se os mesmos conhecem alguma técnica de reconstrução mamária, sendo que 49 (40,83%) responderam que sim e 71 (59,16%) negaram conhecer. Em relação ao encaminhamento à especialidade médica mais preparada para acompanhar e realizar a reconstrução mamária, 93 (77,5%) discentes elegeram a cirurgia plástica e 26 (21,66%) a mastologia. Quanto à possibilidade de reconstrução de mama em pacientes que farão radioterapia adjuvante, 66 (55%) responderam sim, 51 (42,5%) não e 3 (2,5%) não souberam responder. Quanto a esta possibilidade mesmo em pacientes com implantes de silicone, 59 (49,16%) responderam sim, 3 (2,5%) responderam não e 58 (48,33%) afirmaram não saber sobre o assunto. Conclusão: Observou-se que a Mastologia vem ganhando espaço na reconstrução de mama, inclusive no meio acadêmico, devido ao alto percentual de resposta de que a mesma seria mais preparada do que a Cirurgia Plástica para reconstrução mamária.

Introduction: Breast cancer is the most common type of cancer among women in the world and in Brazil, after non-melanoma skin cancer. Our objective was to evaluate the medical students' perception of breast cancer and breast reconstruction. Methods: This is a cross-sectional pilot study composed of students from the fifth and sixth year of medical school, in May 2016. Results: We questioned whether there is a possibility of breast reconstruction after mastectomy, and the response was unanimous (100%). For a better characterization, we asked if the reconstruction could be done at the same time as the mastectomy, and 69 (57.5%) students said yes and 51 (42.5%) denied. In the analysis of surgical knowledge, we asked whether they knew any breast reconstruction technique, and 49 (40.83%) answered yes and 71 (59.16%) denied knowing. With regard to referral to a medical specialist who was better prepared to follow and perform breast reconstruction, 93 (77.5%) students chose plastic surgery and 26 (21.66%) chose mastology. Regarding the possibility of breast reconstruction in patients who need to undergo adjuvant radiotherapy, 66 (55%) answered yes, 51 (42.5%) did not answer, and three (2.5%) did not know how to respond. Regarding this possibility in patients with silicone implants, 59 (49.16%) answered yes, three (2.5%) answered no, and 58 (48.33%) said they did not know about the subject. Conclusion: We conclude that mastology has been gaining immense interest in the field of breast reconstruction, including in the academic world, based on the high percentage of respondents who stated that they are better prepared for this procedure than for plastic surgery for breast reconstruction.

Patent blue and air as an alternative for resection of nonpalpable breast lesions: a case series / Azul patente e ar como uma alternativa para a resseccao de lesoes nao palpaveis de mama: serie de casos

CONTEXT AND OBJECTIVE: Use of mammography for breast cancer screening has resulted in a significantly increased number of patients with nonpalpable radiological findings that need histopathological study for better management. The present study evaluated an alternative to excision of nonpalpable breast lesions, using injection of patent blue (CAS 3536-49-0) dye and air. DESIGN AND SETTING: Cohort study of 64 consecutive patients at a private clinic in the city of Teresina (Piauí), between January 2009 and December 2010. METHODS : The patients had received mammographic diagnoses of nonpalpable breast lesions classified as BI-RADS 3, 4 and 5, with indication of histopathological study. They underwent stereotaxy and/or ultrasound-guided injection of patent blue, for marking and subsequent excision of the lesion. RESULTS : The patients' mean age was 47.7 years. Nodes accounted for 53.1% of the breast abnormalities; microcalcifications, 37.5%; and complex cysts, 9.4%. In 89.1% of cases, the lesions were BI-RADS 4; 7.8% were BI-RADS 5 and 3.1% were BI-RADS 3. The histopathological findings were benign in 70.3% of the cases; atypical hyperplasia, 9.4%; and malignant, 20.3%. Among the malignant cases, 53.8% were carcinoma in situ and 46.2%, invasive carcinoma. The percentage of malignancy was 0% in BI-RADS 3 lesions; 14.3% in BI-RADS 4 and 100% in BI-RADS 5. In the cases of malignancy, the margins were clear in 92.3%. Reoperation to widen the margins was required in one patient. CONCLUSION: Excision of nonpalpable breast lesions marked with patent blue and air was possible in all cases. .

CONTEXTO E OBJETIVOS: A utilização da mamografia no rastreamento para o câncer de mama tem apresentado significativo aumento do número de pacientes com achados radiológicos impalpáveis que, para melhor orientação terapêutica, necessitam de estudo histopatológico. O presente estudo avaliou uma alternativa à ressecção de lesões impalpáveis de mama utilizando injeção de corante azul patente e ar. TIPO DE ESTUDO E LOCAL: Coorte de 64 casos consecutivos de uma clínica particular da cidade Teresina (PI), no período de janeiro de 2009 a dezembro de 2010. MÉTODOS: As pacientes receberam o diagnóstico mamográfico de lesões impalpáveis de mama classes BI-RADS 3, 4 e 5 com indicação para estudo histopatológico. Elas foram submetidas à injeção de azul patente, orientada por estereotaxia e/ou ultrassonografia para marcação e posterior ressecção da lesão. RESULTADOS: A média de idade das pacientes foi 47,7 anos. Os nódulos representaram 53,1% das anormalidades; as microcalcificações, 37,5% e os cistos complexos, 9,4%. Em 89,1% dos casos, as lesões eram BI-RADS 4; 7,8%, BI-RADS 5 e 3,1%, BI-RADS 3. Os achados histopatológicos foram benignos em 70,3% dos casos; com hiperplasia atípica em 9,4% e malignos em 20,3%. Dos casos de malignidade, 53,8% eram carcinoma in situ e 46,2%, carcinoma invasor. O percentual de câncer foi 0% nas lesões BI-RADS 3;14,3% nas BI-RADS 4 e 100% nas BI-RADS 5. Nos casos de neoplasia maligna, as margens estavam livres em 92,3%, sendo necessária reoperação para ampliação de margens em uma paciente. CONCLUSÃO: A ressecção de lesões impalpáveis de mama marcadas com azul patente e ar foi possível em todos os casos. .

Volume of breast tissue excised during breast-conserving surgery in patients undergoing preoperative systemic therapy / Volume de ressecção cirúrgica no tratamento conservador do câncer de mama em pacientes submetidas a tratamento neoadjuvante

PURPOSE: We aimed to determine whether clinical examination could adequately ascertain the volume of tissue to be resected during breast-conserving surgery after neoadjuvant therapy. METHODS: We reviewed the clinical reports of 279 patients with histologically diagnosed invasive breast carcinomas treated with neoadjuvant therapy followed by surgery or with primary surgery alone. We estimated volumes of excised tissues, the volume of the tumor mass and the optimal volume required for excision based on 1 cm of clear margins. The actual excess of resected volume was estimated by calculating the resection ratio measured as the volume of the resected specimen divided by the optimal specimen volume. The study endpoints were to analyze the extent of tissue resection and to ascertain the effect of excess resected tissue on surgical margins in both groups of patients. RESULTS: The median tumor diameter was 2.0 and 1.5 cm in the surgery and neoadjuvant therapy groups, respectively. The median volume of resected mammary tissue was 64.3 cm³ in the primary surgery group and 90.7 cm³ in the neoadjuvant therapy group. The median resection ratios in the primary surgery and neoadjuvant therapy groups were 2.0 and 3.3, respectively (p<0.0001). Surgical margin data were similar in both groups. Comparison of the volume of resected mammary tissues with the tumor diameters showed a positive correlation in the primary surgery group and no correlation in the neoadjuvant therapy group. CONCLUSION: Surgeons tend to excise large volumes of tissue during breast-conserving surgery after neoadjuvant therapy, thereby resulting in a loss of the correlation between tumor diameter and volume of the excised specimen.

OBJETIVO: Foi determinar se a avaliação clínica é adequada na determinação do volume a ser ressecado em cirurgias conservadoras de mama após tratamento neoadjuvante. MÉTODOS: Avaliamos 279 pacientes com diagnóstico histológico de carcinoma invasor de mama submetidas à terapia neoadjuvante seguida de tratamento cirúrgico ou tratadas com cirurgia primária. O volume de tecido excisado, o volume da massa tumoral e o volume ótimo para a excissão cirúrgica baseado em uma margem de 1 cm foram calculados. O excesso de volume excisado foi estimado pelo cálculo da taxa de ressecção determinada pelo volume de tecido excisado dividido pelo volume ótimo para a excisão cirúrgica. Analisamos a extensão da ressecção cirúrgica e o efeito do exesso de tecido ressecado na obtenção de margens cirúrgicas. RESULTADOS: A mediana do diâmetro tumoral foi de 2,0 e 1,5 cm nos grupos de cirurgia primária e terapia neoadjuvante, respectivamente. A mediana do volume de tecido mamário ressecado foi de 64,3 cm³ no grupo de cirurgia primária e de 90,7 cm³ no grupo de tratamento neoadjuvante. A taxa mediana de ressecção nos grupos de cirurgia primária e terapia neoadjuvante foram 2,0 e 3,3 respectivamente (p<0,0001). Os dados relacionados à margem cirúrgica foram similares em ambos os grupos. A comparação do volume de tecido ressecado mostrou correlação positiva no grupo de cirurgia primária, porém não no grupo de tratamento neoadjuvante. CONCLUSÃO: Existe uma tendência dos cirurgiões a removerem maior quantidade de tecido mamário durante cirurgias conservadoras de mama de pacientes que foram submetidas à tratamento neoadjuvante, resultando na perda da correlação entre o diâmetro tumoral e o volume do espécime excisado.

Oncoplastic approach in the conservative treatment of breast cancer: analysis of costs / Abordagem oncoplástica no tratamento conservador do câncer mamário: análise de custos

PURPOSE: To analyze the direct costs of conservative surgical treatment of breast cancer, performed in a university hospital, to the Brazilian National Health Care Public System (SUS), checking the impact of the oncoplastic approach on these costs. METHODS: One hundred thirty eight breast cancer patients who had undergone conservative treatment with oncoplastic approach (n=36) or not (control group, n=102), in the period from 2005 to 2010, were enrolled. Sociodemographic and clinical data were recorded. The direct costs of the surgical procedure were obtained and analyzed. RESULTS: Groups did not differ in regard to age (p=0.963), and patients in oncoplastic group had a longer time of hospital stay (p=0.000). The median direct cost for the oncoplastic group was R$461.00 and for the control group was R$229.00 (p=0.000). CONCLUSION: The oncoplastic approach has generated higher direct costs in conservative surgical treatment of breast cancer to SUS.

OBJETIVO: Analisar os custos diretos do tratamento cirúrgico conservador do câncer mamário, realizado pelo Sistema Único de Saúde (SUS) em um hospital universitário, verificando o impacto da abordagem oncoplástica sobre estes custos. MÉTODOS: Foram incluídas 138 pacientes submetidas ao tratamento conservador do câncer mamário pelo SUS, com abordagem oncoplástica (n=36) ou não (grupo controle, n=102), no período de 2005 a 2010. Foram registrados dados sócio-demográficos e da operação. Os custos diretos do procedimento cirúrgico foram obtidos e analisados. RESULTADOS: Não houve diferença entre os grupos quanto à idade (p=0.963), e o tempo de internação hospitalar foi maior no grupo oncoplástica (p=0,000). A mediana dos custos diretos do grupo oncoplástica foi de R$461,00 e do grupo controle foi de R$229,00 (p=0,000). CONCLUSÃO: A abordagem oncoplástica gerou custos diretos maiores para o tratamento cirúrgico conservador do câncer mamário pelo SUS.

Câncer de mama: alcance do tratamento local / Breast cancer: extent of local treatment

O câncer de mama é a segunda neoplasia mais frequente no mundo e a mais comum entre as mulheres. Apesar de ser considerado um câncer de bom prognóstico se diagnosticado e tratado oportunamente, as taxas de mortalidade continuam elevadas no Brasil; muito provavelmente porque a doença ainda é diagnosticada em estádios avançados. No presente artigo, os autores apresentam definições acerca do câncer de mama e discutem o seu tratamento locorregional.

The breast cancer is the second most frequent tumor in the world and the most common among women. Although it is considered a good prognostic cancer if diagnosed and treated in time, the rates of mortality keep high in Brazil, probably because the disease is still diagnosed in advanced stage. In this article, the authors present definitions about breast cancer and discuss the local treatment.

Cáncer de mama triple negativo: características clínicas y moleculares / Triple negative breast cancer: clinical and molecular characteristics

El cáncer de mama es una enfermedad problema en Venezuela por su incidencia, prevalencia y alta mortalidad. Representa la segunda causa de muerte por cáncer en la mujer venezolana, superado escasamente por el cáncer de cuello uterino. Los carcinomas de mama "triple negativo" se definen por falta de expresión de receptores de estrógenos, progesterona y Her2-Neu. Representan aproximadamente el 15% de todos los cáceres mamarios. Es más frecuente en mujeres pre-menopáusicas jóvenes, en latinoamericanas y en mujeres de raza negra. La mayoría de estos tumores son de tipo ductal, tienen alto grado nuclear e histológico, mayor tasa de recaídas y metástasis y peor pronóstico. La mayoría de los tumores triple negativos pertenecen al tipo molecular de los cánceres de mama tipo basal. El perfil inmunohistoquímico del cáncer de mama triple negativo ha sido investigado extensamente y es altamente heterogéneo. Estos tumores no son tratables con hormonoterapia ni con Trastuzumab y solamente se puede usar quimioterapia en el manejo sistémico. Algunos esquemas de quimioterapia son más efectivos que otros en cáncer de mama triple negativo y hay diversas terapias "emergentes" en investigación clínica.

Breast cancer is a problematic disease in Venezuela bacause of its incidence, prevalence and high mortality rate. It represents the second cause of death by cancer in the venezuelan woman exceeded slighthly by the cervix uterine cancer. Triple negative breast cancers are defined by lack of expression of estrogen, progesterone, and Her2-Neu receptors. This subgroup accounts for 15% of all types of breast cancer and for a higher percentage of breast cancer arising in young pre-menopausal Latin-American women and those of African descent. Histologically, such cancer fall into the molecular type and the basal subgroup of the breast cancer. Most of them are ductal with a high nuclear and histological grade, a higher rate of replase and metastasis and a worse prognosis. The triple negative breast cancer immunohistochemical profile has been extensively investigated and is higly heterogeneous; it is not treated with hormone therapy or with Trastuzumab and only chemotherapy in the systemic way can be used. Some chemoterapy schemes are more effective for the treatment of triple negative breast cancer and there are also "emergent" therapies in clinical investigation.

Es carcinoma lobulillar infiltrante igual a carcinoma ductal infiltrante?: seguimiento a largo plazo / Is lobulillar infiltrante carcinoma equal to ductal infiltrante carcinoma?: long term follow

Comparar carcinoma lobulillar infiltrante y carcinoma ductal infiltrante a largo plazo según estadio, tratamiento quirúrgico, terapia neoadyuvante, adyuvante. Estudiamos en la base de datos de CECLINES 841 pacientes, el lobulillar representa 7,25% (61) y ductal 51,24% (431). El seguimiento global 22 años con promedio de 5 años. La sobrevida global: lobulillar 68,1% vs. 60,9% ductal (P=0,772), por estadio fue: I lobulillar 96,3% ductal 90,5 II 94,4% y 88,4% III 90,5% 83,2% (P=0,023). La expresión de receptores de estrógenos positivos en comparación a los CDI fue 87,7% vs. 74,7%,(P=0,031) sobrevida 96,9% vs. 94,0% (P=0,033). El tratamiento preservador del lobulillar en comparación aductal 57,4% vs. 63,2% (P=0,949) y la sobrevida 85,4% vs. 82,9% (P=0,001). La sobrevida de lobulillar sometidos a quimioterapia primaria, quimioterapia adyuvante, radioterapia y hormonoterapia adyuvante en relación al grupo ductal fue 93,4% vs. 91,3%, 91,5% vs. 89,7%, 92,5% vs. 89,8% 92,5% vs. 88,4%, respectivamente (P<0,05). La sobrevida global es igual, la sobrevida por estadio favorece al lobulillar estos presentan más receptores positivos y sobrevida mejor. La tendencia a tratamiento preservador en lobulillar es mayor encontrando excelentes cifras de sobrevida. Dado el perfil hormonal y sobrevida según receptores las pacientes con lobulillar infiltrante son candidatas a participar en protocolos de hormonoterapia primaria. Generalmente el tratamiento para ambos grupos es similar.

Compare infiltrante lobulillar carcinoma and ductal carcinoma in long-term follow up as stage surgical treatment, neoadyuvante, adjuvant therapy. We studied in CECLINES data base 841 patients; lobulillar represents 7.25% (61) and 51.24% ductal (431). The overall followup was up to twenty two years with an average of five years. The overall survival for lobulillar was 68.1%and for ductal 60.9% (P=0.772), the survival according to state was: I lobulillar 96.3% ductal 90.5, II 94.4% vs. 88.4 III 90.5 and 83.2 respectively (P=0.023). Estrogen receptors positive expression for lobulillar compared to ductal was 87.7% vs. 74.7%, (P=0.031) and its survival 96.9% vs. 94.0% (P=0.033). The breast conserving surgery for lobulillar compared to ductal was 57.4% vs. 63.2% (P=0.949) survival 85.4% vs. 82.9% (P=0.001). The survival reported for patients with lobulillar who received neoadyuvante chemotherapy adjuvant chemotherapy radiotherapy and adjuvant hormonotherapy compared to ductal was 93.4% 91.3%, 91.5% 89.7%, 92.5% 89.8% 92.5% 88.4%, respectively P<0.05. The overall survival is equal, survival favors. The lobulillar have more positive receptors and survival is better. The tendency to conservative treatment in lobulillar is increasingly. Given the hormonal profile and survival according to estrogen receptors patients with ILC, are probably good candidates to participate in neoadyuvante hormone therapy protocols. Usually the treatment is the same or similar for both groups.

Tratamiento preservador del cáncer de la mama: dos años de experiencia / Conservative breast cancer treatment: two years of experience

Experiencia de nuestra institución en tratamiento preservador del cáncer de mama, analizando cirugía preservadora en términos de recidiva local, sobrevida global y libre de enfermedad. Estudio descriptivo, retrospectivo durante 2004-2005, en pacientes sometidos a tratamiento preservador: la realización de mastectomía parcial oncológica con márgenes negativos, evaluación quirúrgica de axila mediante técnica del ganglio centinela o disección axilar, el tratamiento adyuvante con radioterapia, y quimioterapia en los casos que tuviesen indicación. 132 cirugías conservadoras. Edad media 51,49 años, Tipo histológico más frecuente fue carcinoma ductal infiltrante (70,06 por ciento), (85,94 por ciento) fueron estadio I y II. La cirugía que más se realizó fue la mastectomía parcial oncológica más disección axilar (80 pacientes, 61,87 por ciento). 10,6 por ciento recibieron neoadyuvancia con quimioterapia. El promedio de ganglios obtenidos fue de 11,37, el 62,6 por ciento estado patológico axilar 0.50 por ciento expresaron receptores de estrógeno y progestágenos positivos el 13,17 por ciento sobre expresaron el Her2neu. 66,66 por ciento recibió quimioterapia adyuvante, 79,84 por ciento radioterapia adyuvante. 56,58 por ciento terapia hormonal adyuvante, seguimiento 39,89 meses promedio. 88,88 por ciento vivas libres de enfermedad, 2,22 por ciento vivas con recaída local, 5,92 por ciento viva con metástasis, 1,48 por ciento viva con recaída local y metastásica 1,07 por ciento muerta por enfermedad. El intervalo libre de enfermedad promedio fue de 25,8 meses y la sobrevida global a los 5 años de 98,24 por ciento. El tratamiento preservador es una terapia primaria efectiva en casos de cáncer de mama estadio I y II.

Presented the experience in our institution in the conservative treatment of breast cancer, we analyzed the surgery, local recurrence, and the global super life, and the disease free survival. These are a descriptive and retrospective study during 2004-2005 in patients underwent conservative treatment: realize of partial oncology mastectomy with negative margins surgical evaluation of axillaries sentinel node technique or axillaries dissection. The adjuvant treatment with radiation therapy and chemotherapy when there are indicated in the patients. We realize 132 conservative surgery, median ages of patients were 51.49 histological type more frequent was ductal infiltrante carcinoma (70.06 percent), (85.94 percent) were stage I and II. The surgical more frequent were partial oncology mastectomy with axillaries dissection (80 patients, 61.87 percent). 10.6 percent received adjuvant chemotherapy. The average of finding nodes was 11.37, the 62.6 percent pathological axillaries state were 0.50 percent expression positive estrogen and progestagen receptors 13.17 percent super expression of Her2neu. 66.66 percent received adjuvant chemotherapy, 79.84 percent adjuvant radiation therapy 56.58 percent adjuvant hormonal therapy. Average vigilance was 39.89 months. 88.88 percent alive free disease, 2.22 percent alive with local recurrence, and 5.92 percent alive with metastases. 1.48 percent alive with local and metastasis recurrence 1.07 percent dead for disease. The free interval of disease was 25.8 month and the global super life to 5 years 98.24 percent. The conservative treatment is a primary and effective in breast cancer therapy for stage I and II.

Actividad quirúrgica en el servicio de mastología del Centro Nacional de Oncología de Luanda (2007) / Surgical activity in the mastology service of the National Center of Oncology, Luanda, Angola (2007)

INTRODUCCIÓN. Las enfermedades mamarias son un problema de salud también en los países subdesarrollados. Ello motivó la creación del Servicio de Mastología en el Centro Nacional de Oncología de Luanda (Angola), en el año 2007. La presente investigación tuvo como objetivo describir la actividad quirúrgica de este centro durante el año 2007. MÉTODOS. Se realizó un estudio transversal descriptivo que incluyó a los 183 pacientes sometidos a algún tipo de cirugía mamaria en el Servicio de Mastología en el Centro Nacional de Oncología de Luanda durante ese período. Los datos fueron recogidos en un formulario confeccionado por los autores y se procesaron mediante el programa estadístico SPSS (versión 13.0). La información fue resumida en frecuencias absolutas y porcentajes. RESULTADOS. En los pacientes intervenidos quirúrgicamente predominaron las enfermedades benignas sobre las malignas, con alta incidencia de fibroadenomas gigantes. La tumorectomía fue el tipo de cirugía más empleada en las enfermedades benignas, acompañadas de técnicas de cirugía plástica en pacientes con fibroadenoma gigante. Todos los pacientes con tumores malignos requirieron cirugías radicales en correspondencia con la estadificación tardía que predominó en esta serie de casos. El índice de complicaciones quirúrgicas fue bajo. Las enfermedades de la mama constituyen un problema de salud en la población estudiada. El diagnóstico tardío de tumores en etapas avanzadas determina el tratamiento quirúrgico radical sobre el conservador(AU)

INTRODUCTION. Breast diseases are also a health problem in developing countries. Hence, the creation of the Mastology Service in the National Center of Oncology of Luanda, Angola in 2007. The aim of present paper was to describe the surgical activity of this institution during 2007. METHODS. A descriptive and cross-sectional study was conducted including 183 patients undergoing some type of breast surgery in above mentioned Service during that period. Data were registered in a form designed by authors and processed using the SPSS statistical program (version 13.0). Information was summarized in absolute frequencies and percentages. RESULTS. In patients operated on there was predominance of benign diseases and plastic surgery techniques in those patients presenting with giant fibroadenoma. All patients with malignant tumors underwent radical surgeries according the late staging present in this series of cases. The rate of surgical complications was low. NS. Breast diseases are a health problem in study population. Late diagnosis of tumors in advanced stages determines the radical surgical treatment above the conservative one(AU)

Biópsia do linfonodo sentinela para o câncer de mama com anestesia local / Sentinel node biopsy for breast cancer under local anesthesia

Introdução: A técnica da biópsia do linfonodo sentinela (BLS) e considerada padrão-ouro como método preditor do comprometimento axilar para o câncer de mama. Entretanto, a avaliação perioperatória do linfonodo sentinela tem desvantagens. Tentando minimizar as desvantagens, alguns serviços começaram a realizar a pesquisa do linfonodo sentinela sob anestesia local. O objetivo principal deste trabalho prospectivo e demonstrar nossa experiência na pesquisa do linfonodo sentinela, realizada sob anestesia local, e demonstrar a viabilidade deste procedimento. Métodos: Trata-se de um estudo prospectivo que tem como alvo as pacientes matriculadas na Fundação Pio XII - Hospital de Câncer de Barretos, as quais são portadoras de carcinoma da mama. As pacientes foram submetidas à biópsia do linfonodo sentinela sob anestesia local, no período de janeiro a novembro de 2009, conforme protocolo estabelecido. Resultados: No período de janeiro a dezembro de 2009, foram realizados 41 procedimentos da pesquisa de linfonodo sentinela sob anestesia local. Durante o procedimento sob anestesia local, a média dissecada foi de 2,4 (0-5) linfonodos. Em quatro casos, o resultado anatomopatológico dos linfonodos ressecados foi positivo; houve um caso para macrometástases e três restantes para micrometástases. Em todos os pacientes, o procedimento foi realizado sem intercorrências, utilizando-se de doses de anestésicos muito inferiores aos seus níveis tóxicos. Todos os pacientes evoluíram sem qualquer tipo de complicação intra ou pós-operatória. Conclusão: A pesquisa do linfonodo sentinela sob anestesia local e um procedimento factível que traz pouco desconforto para o paciente, devendo ser indicado sempre que possível. Apresenta inúmeras vantagens, comparando-se com a técnica sob anestesia geral.

Introduction: The technique of sentinel lymph node biopsy (SIB) is the gold standard method to predict the axilar status for breast cancer. However, the intraoperative evaluation of the sentinel lymph node has disadvantages. Some services, attempting to minimize these disadvantages, have begun to carry out the sentinel lymph node biopsy under local anesthesia. The aim of this prospective study is to demonstrate our experience in the sentinel lymph node biopsy, which was carried out under local anesthesia, and this procedure's feasibility. Methods: This is a prospective study that targets the patients enrolled in the Hospital de Câncer de Barretos, suffering from breast cancer. The patients underwent sentinel lymph node biopsy under local anesthesia from January to November, 2009, according to the established protocol. Results: From January to December, 2009, 41 research procedures were performed of the sentinel lymph node under local anesthesia. During the procedure under local anesthesia, the dissected average was 2.4 (0-5) lymph nodes. In four cases, the result of the resected pathological lymph nodes was positive; in one case for macrometastases; and the remaining three for micrometastases. In all patients, the procedure was performed uneventfully, using doses of anesthetic below their toxic levels. All patients survived without any complications intra- or postoperatively. Conclusion: The sentinel lymph node biopsy under local anesthesia is a feasible procedure that brings little discomfort to the patient, and should be indicated whenever possible. It has many advantages, when comparing with the technique under general anesthesia.

"V"-technique as a method of breast conserving surgery in multifocal and T2 invasive breast cancers situated in the upper outer quadrant / La técnica "V" como método quirúrgico para conservar las mamas en cánceres de mama invasivos T2 y multifocales situados en el cuadrante superior externo

OBJECTIVE: To assess the oncologic and cosmetic outcomes in women with multifocal breast cancers or T2 tumours with diameters larger than 3 cm situated in the upper outer quadrant who were treated with "V"-technique. METHODS: From July 1999 till June 2003, 44 conserving surgeries with "V"-technique using a local rotational flap were performed. Localization of tumours was in the upper outer quadrant. All solid tumours were larger than 3 cm in diameter. In all patients, axillary lymph node dissection was performed. All the patients received postoperative radiotherapy. Mean follow-up was 58 months. RESULTS: Out of 44 conserving surgeries with "V"-technique, an adequate distance of tumour from the margins was obtained in 84.1% (37/44). Out of 37patients who underwent conserving surgery with this technique, the cosmetic result was favourable in 83.78% (31/37). None of these patients had a corrective surgery such as reduction mammaplasty or mastopexy. Mean weight of excised tissue was 215 g. The 5-year local recurrence rate was 10.8%. The 5-year metastasis-free survival rate was 81,1%. The 5-year overall survival rate was 86.5 %. CONCLUSIONS: Surgical treatment of multifocal and T2 breast cancers larger than 3 cm in diameter situated in the upper outer quadrant and performed with "V"-technique gives a good aesthetic result and enables a wide resection of breast tissue around the tumour.

OBJETIVO: Evaluar los resultados oncológicos y cosméticos en las mujeres con cánceres multifocales de mama o tumores T2 de diámetro mayor de 3 cm, situados en el cuadrante superior externo, en pacientes tratadas con la técnica "V". MÉTODOS: De julio 1999 hasta junio de 2003, se realizaron 44 cirugías conservadoras usando la técnica "V" con colgajo local de rotación. Los tumores se hallaban localizados en el cuadrante superior. Todos los tumores sólidos tenían más de 3 centímetros de diámetro. A todas las pacientes se les practicó la disección del ganglio linfático axilar. Todas las pacientes recibieron radioterapia postoperatoria. El seguimiento promedio fue de 58 meses. RESULTADOS: De las 44 cirugías conservadoras con la técnica "V", se obtuvo una distancia adecuada del tumor en 84.1% (37/44) desde los márgenes. De 37 pacientes que tuvieron cirugía conservadora con esta técnica, el resultado cosmético fue favorable en 83.78% (31/37). A ninguna de estas pacientes se les realizó cirugías correctivas tales como mamoplastia de reducción, o mastopexia. El peso promedio del tejido extirpado fue 215 g. La tasa de recurrencia local quinquenal fue de 10.8%. La tasa de supervivencia quinquenal libre de metástasis fue 81, 1%. La tasa general de supervivencia fue de 86.5%. CONCLUSIONES: El tratamiento quirúrgico de los cánceres de mama T2 y multifocales mayores de 3 cm. de diámetro situados en el cuadrante superior externo y realizado con la técnica "V" produce un buen resultado estético y permite una resección amplia del tejido mamario alrededor del tumor.

Evolución clínica de las pacientes sometidas a cirugía conservadora versus mastectomía radical en pacientes con cáncer de mama estadio i-iii a en el servicio de oncología durante el periodo comprendido de enero 2007 a enero 2010 en el hospital Bertha Calderón Roque / The clinical outcome of patients undergoing radical mastectomy versus conservative surgery in patients with breast cancer stage i-iii to the oncology service during the period January 2007 to January 2010 at the Bertha Calderon Roque hospital

El presente trabajo monográfico se realizó en el servicio de Oncología del Hospital Bertha Calderón Roque, durante el período comprendido de Enero 2007- Enero 2010. El universo estuvo constituido por 349 paciente, siendo la muestra de 104 pacientes con cáncer de mama en los estadios clínicos I-IIIA, las cuales se seleccionaron en 2 grupos; el primer grupo corresponde a las que se les realizó cirugía conservadora (57) y el segundo grupo a las que se les realizo mastectomía radical (47). El grupo etéreo más afectado corresponde a mayores de 50 años en ambos grupos de estudio 54.4% (31/57) en la cirugía conservadora y 65.9% (31/47) en la mastectomía radical; seguido del grupo comprendido entre 35-49 años de edad, correspondiendo a 43.85% (25/57) en la cirugía conservadora y 31.92% (15/47) en la mastectomía radical. El tipo histológico predominante es el Carcinoma ductal infiltrante en ambos grupos de estudio, correspondiendo el 82.4% (47/57) al grupo de cirugía conservadora y 89.36% (42/47) en el grupo de mastectomía radical. El estadio clínico predominante en la cirugía conservadora fue el IIA con 42.1% (24/57) y en el grupo de mastectomía radical fue las no estadificada por cirugía con 27.5% (13/47). Los criterios quirúrgicos utilizados para la realización de este tipo de cirugía son los mismos establecidos por la literatura revisada...

Cirugía oncoplástica de la mama: cómo mejorar la resecabilidad en cirugía conservadora asegurando la estética / Oncoplastic surgery for breast cancer

Background: In breast cancer surgery, the association of reductive mammoplasty to oncological excisión, allows more extensive excisions, reducing radical surgery and preventing secondary deformities. This is called oncoplastic or tumor specific mammary reconstruction. Aim: To report 37 patients in whom oncoplastic surgery was used. Material and Methods: Retrospective descriptive series of 37 patients aged 38 to 65 years, subjected to oncoplastic mammary surgery, that were followed for a median of 42 months. Results: Eighty six percent considered the cosmetic result of surgery as satisfactory. One patient had a local relapse associated to systemic dissemination at 16 months. One patient died and one is under hormonal treatment for bone metastases. No significant complications or delays in oncological therapies were recorded. Conclusions: Oncoplastic surgery may avoid mastectomy and prevent deformities in breast cancer surgery.

Conservar la mama se considera uno de los objetivos importantes en el tratamiento del cáncer. Frecuentemente la relación entre el tamaño y la localización tumoral impide la cirugía conservadora con un buen resultado estético u obliga a realizar una mastectomía, lo que empobrece la calidad de la sobrevida. Asociar técnicas de mamoplastía reductiva a la resección oncológica ha permitido aumentar la extensión de las resecciones, disminuyendo las cirugías radicales o previniendo las deformidades secundarias. Es lo que llamamos oncoplástica mamaria (OPM) o reconstrucción mamaria tumor específica. Presentamos una serie descriptiva retrospectiva de 37 pacientes en quienes usamos OPM como alternativa a la mastectomía. Un 86 por ciento consideró el resultado cosmético como satisfactorio. La mediana de seguimiento fue 42 meses. Una paciente ha tenido recurrencia local asociada a diseminación sistémica a los 16 meses. Una paciente falleció y otra está en tratamiento hormonal por metástasis óseas. No hubo complicaciones importantes en la serie ni retardo significativo de las terapias secuenciales. Concluimos que esta técnica permite evitar mastectomías y prevenir deformidades en cirugía conservadora estándar.